Investigating Effects in Intestinal Permeability of Rich in Beta-glucans Pleurotus Eryngii Mushrooms Fermentation Supernatants: an Ex-vivo Study

Development of a Novel Functional Food Enriched With Beta-glucans Isolated From Edible Mushrooms of Greek Habitats

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05446610

Acronym

FUNglucan

Enrollment

Registered

2022-07-06

Start date

2020-03-17

Completion date

2022-06-17

Last updated

2022-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

paracellular permeability, transcellular permability, Pleurotus eryngii, beta glucan, prebiotic

Brief summary

The aim of the present study was to investigate the ability of Pleurotus eryngii mushrooms fermentation products (FS) to counteract induced intestinal hyperpermeability in human colonic tissues in an ex vivo system.

Detailed description

Collection of colon biopsies through sigmoidoscopy procedure will take place and the collected biopsies will be mounted in Ussing Chambers. Already collected fermentation supernatants will be added to the mucosal side of the biopsy together with a stressor and two permeability markers, in order to investigate the effects of the fibre fractions on both paracellular and transcellular permeability.

Interventions

OTHERFermented product of Pleurotus eryngii mushroom

I Stimulation of human colonic biopsies with the fermented product of Pleurotus eryngii mushroom

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

1. Signed consent prior to any study related procedures 2. Age 18-65 years 3. Willing to abstain from regular consumption of prebiotics/probiotics products or medication known to alter gastrointestinal functions at least 4 weeks prior to the study visits

Exclusion criteria

1. Previous complicated gastrointestinal surgery 2. Presence of gastrointestinal disorder or any disorder which the principal investigator considers to affect the results of the study 3. Current diagnosis of psychiatric disease 4. Current and past diagnosis inflammatory gastrointestinal disease (e.g. Irritable Bowel Disease) 5. Systemic use of antibiotics or steroids medications in the last 3 months 6. Frequent use of NSAID (Non Steroidal Anti Inflammatory Drugs) the last 2 months prior to study visits 7. Regular consumption of prebiotic/probiotic products for the past 4 weeks 8. Abuse of alcohol or drugs 9. Frequent use of laxatives, anti-diarrheal, anti-cholinergic within last 12 weeks prior to study visits 10. Pregnancy and breast-feeding

Design outcomes

Primary

Measure	Time frame	Description
Change from baseline of barrier function (paracellular permeability) after 90 minutes of ex vivo stimulation of the colonic biopsies.	Barrier function will be measured at baseline and after 90 minutes of ex vivo stimulation of the colonic biopsies.	Barrier function (paracellular permeability) will be evaluated with the use of marker related this permeability, through immunofluoresence.
Change from baseline of barrier function (transcellular permeability) after 90 minutes of ex vivo stimulation of the colonic biopsies.	Barrier function will be measured at baseline and after 90 minutes of ex vivo stimulation of the colonic biopsies.	Barrier function (transcellular permeability) will be evaluated with the use of marker related to this permeability, through ELISA tecnhique.

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026